Literature DB >> 16882318

Synthesis and pharmacological activity of 2-(substituted)-3-{2-[(4-phenyl-4-cyano)piperidino]ethyl}-1,3-thiazolidin-4-ones.

Orazio Mazzoni1, Antonio Mazzella di Bosco, Paolo Grieco, Ettore Novellino, Alessia Bertamino, Francesca Borrelli, Raffaele Capasso, Maria Vittoria Diurno.   

Abstract

Loperamide is a well-known peripherally acting opiate used for the treatment of diarrhoea. To gain more knowledge on the structure-activity relationships of antidiarrhoeal drugs and to develop new active molecules, a series of aryl-cyano-piperidinoalkyl-thiazolidinones related to Loperamide was synthesized and screened for antidiarrhoeal activity in mice by castor oil test. To characterize the potency and toxicity of the synthesized compounds ED50 and LD50 values were also determined. The thiazolidinones 2-6 displayed antidiarrhoeal activity at doses ranging between 15 and 82 mg/kg. Although the results show that the synthesized compounds are 15- to 80-fold less active respect to the reference compound, Loperamide, they are much less toxic (> or = 1000 mg/kg and 108.9 mg/kg, respectively). Besides, to evaluate the involvement of opioid receptors in antidiarrhoeal activity, Naloxone was administered prior to test the 2-phenyl-3-{2-[(4-phenyl-4-cyano)piperidino]ethyl}-1,3-thiazolidin-4-one (2), the more active compound of this series. The results obtained by this study, suggest that the antidiarrhoeal activity of this series of thiazolidinone derivatives could involve the opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882318     DOI: 10.1111/j.1747-0285.2006.00399.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  2 in total

Review 1.  Thiazoles and Thiazolidinones as COX/LOX Inhibitors.

Authors:  Konstantinos Liaras; Maria Fesatidou; Athina Geronikaki
Journal:  Molecules       Date:  2018-03-18       Impact factor: 4.411

2.  Antimicrobial and immunomodulatory activity induced by loperamide in mycobacterial infections.

Authors:  Esmeralda Juárez; Andy Ruiz; Omar Cortez; Eduardo Sada; Martha Torres
Journal:  Int Immunopharmacol       Date:  2018-09-27       Impact factor: 4.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.